KNSA vs SLB · P/E 53, rev $677.6M vs P/E 12, rev $8.97B
Kiniksa Pharmaceuticals Ltd (KNSA) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the KNSA and SLB stock pages for the full models.
Not investment advice.